Net Income

With its NAD+ technology featured in Forbes, biotech brand Aramore is challenging marketing hype with scientific rigor and a vision for longevity.

BitGo and New Frontier Labs are launching FYUSD, a stablecoin bringing U.S. regulatory standards to Asia and paving the way for AI-driven finance.

As Home Instead names its 10 Care Pros of the Year, the awards highlight both profound human compassion and the urgent need to address a critical caregiver shortage.

After a period of uncertainty, the digital asset firm has regained compliance with Nasdaq's bid price rule, a key step for its institutional ambitions.

enGene hits the road for key investor conferences, showcasing a promising non-viral gene therapy for a tough-to-treat bladder cancer. Will it succeed?

F&G Annuities & Life declared its quarterly dividend, offering a sign of stability even as a recent earnings report and stock drop raise questions.

Following massive asset sales and billions in dividends, Array Digital reports surging tower revenue and an optimistic forecast for its new 5G future.

As demand for data centers and electrification soars, nVent brings in veteran Mellinda Devese to transform its global supply chain and secure future growth.

After selling its wireless unit, TDS reports soaring profits and announces aggressive new growth targets for its fiber broadband and tower businesses.

Stunning high-grade gold samples, including one at 250 g/t, prompt Yukon Metals to consolidate a historic mining area near Whitehorse.

As Ranger Energy Services prepares to release its Q4 results, investors are watching closely after a tough Q3. Will the report signal recovery or continued pain?

Bitdeer leverages complex financial deals to refinance debt and fund a major expansion into the booming AI and high-performance computing market.

The chemical giant's dramatic dividend cut ends a 14-year growth streak, raising questions about sector health and long-term investor returns.

A new stamp-sized oral film could replace the dreaded epinephrine needle. Aquestive's Anaphylm shows promise, but faces regulatory and market hurdles.

The biotech firm landed $1M at a premium, a sign of investor faith. But with past regulatory hurdles, can this cash pave a new path for its NurOwn® therapy?

Lamar Advertising reports a massive 63.4% jump in annual net income, driven by strategic asset sales and operational growth, signaling a bullish 2026.

The REIT is offering a high 9.75% yield for new notes, but investors who refuse the swap could see their current protections vanish. A critical choice looms.

As Sectra prepares its nine-month report, all eyes are on its performance as a key indicator for the converging medical IT and cybersecurity sectors.

As Europe's landmark MiCAR regulation takes hold, KuCoin EU expands its Vienna compliance team, signaling a strategic shift toward regulated growth.

Sai Life Sciences' plan to hire 700+ professionals underscores a global shift, positioning India as a critical hub for pharmaceutical R&D and manufacturing.